Summary

Overview
Global Whole Genome Sequencing market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Specifying the order of bases is called sequencing. Whole genome sequencing is a laboratory process that specifies the order of bases in the genome of an organism in one operation. Whole-genome sequencing (WGS) is a complete technique for analyzing complete genomes. Genomic data has been instrumental in determining inherited conditions, marking the mutations that cause cancer advancement, and tracking infection outbreaks.
Market Dynamics: Drivers & Restraints
Increasing Advanced Products Introductions
The increasing advanced products introductions into the market is expected to boost the global market growth during the forecast period. For instance, in September 2022, Illumina, Inc. introduced its NovaSeq X series platforms, including NovaSeq X Plus and NovaSeq X. The production-scale sequencers can yield around 20,000 whole genomes in a year, which delivers 2.5 times better throughput than existing sequencers. Moreover, in January 2023, Qiagen Digital Insights (QDI) introduced Qiagen CLC Genomics Workbench Premium software that analyses the whole genome data in 25 minutes for almost USD 1 in cloud computing costs.
Furthermore, the technological advancements, rise in research activities, increaseing investments, growing cases of chronic and heridaitery conditions and increaseing awareness are among the other additional factors boosting the global market growth during the forecast period.
Lack of Skilled Professionals
The lack of skilled professionals is expected to hamper the global market growth during the forecast period. Furthermore, the the ethical and legal limitaions associated with sequencing are other additional factors hampering the global market growth during the forecast period.
Segment Analysis
The global whole genome sequencing market is segmented based on product, type, application, end user and region.
Services Products are Expected to Dominate Market
Owing to the increase in the introductions of new genome sequencing services into the market and the low-cost genome sequencing are boosting the segment growth dominating the global market during the forecast period. For instance, in February 2021, Stanford Medicine introduced its whole genome sequencing in-house service for the detection of the reason for disorders, particularly cardiovascular disease, and assists in the identification of target therapies. Moreover, in February 2020, Nebula Genomics introduced a lower-cost whole genome sequencing service, which is obtainable direct-to-consumer at USD 299.
Geographical Analysis
North America is Expected to Dominate the Global Market
Owing to the research advancements and the presence of major players such as Illumina, Inc., with well-established R&D and manufacturing facilities in the region holding the majority of the global market through distinct market tactics, ensures North America's dominance on the global market in the forecast period.
For instance, in March 2022, in a substantial breakthrough, researchers at a US-based gene analytics corporation asserted that they could decode nearly all the DNA of days-old embryos produced through in vitro fertilization (IVF). Moreover, in November 2021, Illumina and Genetic Alliance began a USD 120 million multinational endeavor the iHope Genetic Health program. This endeavor seeks to present Whole Genome Sequencing (WGS) access to diverse individuals affected by genetic conditions worldwide.
COVID-19 Impact Analysis
The increased use of genomic sequencing in response to the pandemic has had a positive impact on the market. One example of this is the COVID-19 Genomics U.K. Consortium, which was launched by the U.K. Government in March 2022 to sequence the genomes of the SARS-CoV-2 virus. The consortium received an investment of approximately USD 22 million (EUR 20 million) to map the spread of the virus. Additionally, the Department of Defense developed a SARS-CoV-2 Whole Genome Sequencing Action Plan in December 2022, in response to the COVID-19 pandemic.
Market Segmentation
By Product
• Instruments
• Consumables
• Services
By Type
• Large Whole Genome Sequencing
• Small Whole Genome Sequencing
• Other
By Application
• Diagnostics
• Drug Discovery
• Precision Medicine
• Epidemiological Studies
• Others
By End User
• Academic & Research Institutes
• Hospitals and Diagnostic Centers
• Pharmaceutical & Biotechnology Companies
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In October 2023 Congenica, a digital health corporation delivering software and solutions for the analysis and interpretation of genomic data at scale, expanded its contract by 2 years for the Hong Kong Genome Project (HKGP), the first large-scale genome sequencing initiative in Hong Kong.
• In October 2023, PacBio, a top developer of high-quality, highly precise sequencing solutions, introduced PacBio WGS Variant Pipeline, a complete, standardized computational approach for HiFi whole genome sequencing (WGS) data analysis.
• In April 2021, Sedia Biosciences Corporation introduced the Sedia COVID-19 whole genome sequencing service, which delivers whole genome sequencing of SARS-CoV-2 specimens for the identification of novel variants and their surveillance.
Competitive Landscape
The major global players in the market include Illumina; Inc., Thermo Fisher Scientific, Inc., Oxford Nanopore Technologies, QIAGEN, Agilent Technologies, PerkinElmer Genomics, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, PACBIO and PierianDx.
Why Purchase the Report?
• To visualize the global whole genome sequencing market segmentation based on product, type, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of whole genome sequencing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global whole genome sequencing market report would provide approximately 69 tables, 69 figures and 184 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Application
3.3. Snippet by Type
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Advanced Products Introductions
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Lack of Skilled Professionals
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Patent Analysis
5.5. Technology and Trend Analysis
5.6. Unmet Needs
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
7.1.2. Market Attractiveness Index, By Product
7.2. Instruments*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Consumables
7.4. Services
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Diagnostics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Drug Discovery
8.4. Precision Medicine
8.5. Epidemiological Studies
8.6. Others
9. By Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.1.2. Market Attractiveness Index, By Type
9.2. Large Whole Genome Sequencing*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Small Whole Genome Sequencing
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Academic & Research Institutes*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hospitals and Diagnostic Centers
10.4. Pharmaceutical & Biotechnology Companies
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Illumina; Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Thermo Fisher Scientific, Inc.
13.3. Oxford Nanopore Technologies, Inc.
13.4. QIAGEN
13.5. Agilent Technologies
13.6. PerkinElmer Genomics,
13.7. Bio-Rad Laboratories, Inc.
13.8. F. Hoffmann-La Roche Ltd,
13.9. PACBIO
13.10. PierianDx
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us